Read more

June 13, 2023
1 min watch
Save

VIDEO: TTHX1114 speeds up vision recovery after Descemet stripping only, cataract surgery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • TTHX1114 protects corneal endothelial cells against oxidative stress.
  • TTHX1114 showed the ability to accelerate recovery of vision after Descemet stripping only with or without cataract surgery.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, David Eveleth, PhD, CEO of Trefoil Therapeutics, speaks about the results of TTHX1114 following Descemet stripping only and cataract surgery.

This regenerative product has the ability to protect corneal endothelial cells against oxidative stress, which is the mechanism of damage in phacoemulsification, leading to the loss of endothelial cells and corneal edema.

“A set of clinical data show that we can accelerate the recovery of good vision and the resolution of edema in these patients following DSO with or without cataract surgery,” Eveleth said.

The company has completed a phase 1 safety study for topical TTHX1114 and expects to move to phase 2 later this year.